Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.

Yao-Chun Hsu Mindie H NguyenLein-Ray MoMing-Shiang WuTzeng-Huey YangChieh-Chang ChenCheng-Hao TsengChi-Ming TaiChun-Ying WuJaw-Town LinYasuhito TanakaChi-Yang Chang

Published in: Alimentary pharmacology & therapeutics (2018)

Serum HBcrAg and HBsAg levels were independent predictors of off-NA relapse and can be factored into a risk score to guide treatment cessation in patients with CHB.

Keyphrases

hepatitis b virus
stem cells
free survival
replacement therapy
cell therapy